TrialThe Journal of infectious diseases2014

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.

Antonella Castagna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.